Unique determinants of neuraminidase inhibitor resistance among N3, N7, and N9 avian influenza viruses

Journal of Virology

Volumn 89, Issue 21, 2015, Pages 10891-10900

  Song, Min Suk ^a,b   Marathe, Bindumadhav M ^a   Kumar, Gyanendra ^a   Wong, Sook San ^a   Rubrum, Adam ^a   Zanin, Mark ^a   Choi, Young Ki ^b   Webster, Robert G ^a   Govorkova, Elena A ^a   Webby, Richard J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b Chungbuk National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; PERAMIVIR; SIALIDASE INHIBITOR; ZANAMIVIR; ENZYME INHIBITOR; GENETIC MARKER; SIALIDASE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTIVIRAL RESISTANCE; ARTICLE; AVIAN INFLUENZA VIRUS; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVE SITE; HUMAN; HUMAN CELL; INFLUENZA A VIRUS (A/PUERTO RICO/8/1934(H1N1)); MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; VIRUS GENE; VIRUS RECOMBINANT; VIRUS TRANSMISSION; ZOONOTIC TRANSMISSION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DOG; DRUG EFFECTS; DRUG RESISTANCE; GENETIC ENGINEERING; GENETIC MARKER; GENETICS; INFLUENZA A VIRUS; MDCK CELL LINE; MOLECULAR MODEL; SPECIES DIFFERENCE; VIRAL PLAQUE ASSAY;

ANIMALS; DOGS; DRUG RESISTANCE; ENZYME INHIBITORS; GENETIC ENGINEERING; GENETIC MARKERS; HUMANS; INFLUENZA A VIRUS; MADIN DARBY CANINE KIDNEY CELLS; MODELS, MOLECULAR; MUTAGENESIS; NEURAMINIDASE; SPECIES SPECIFICITY; VIRAL PLAQUE ASSAY;

EID: 84945188452     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01514-15     Document Type: Article

References (73)

1. CDC. 2006. High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents- United States, 2005-06 influenza season. MMWR Morb Mortal Wkly Rep 55:44-46.
2. Pizzorno A, Abed Y, Boivin G. 2011. Influenza drug resistance. Semin Respir Crit Care Med 32:409-422. http://dx.doi.org/10.1055/s-0031 -1283281.
3. Webster RG, Govorkova EA. 2014. Continuing challenges in influenza. Ann N Y Acad Sci 1323:115-139. http://dx.doi.org/10.1111/nyas.12462.
4. Colman PM. 1994. Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci 3:1687-1696. http://dx.doi.org/10.1002/pro .5560031007.
5. Kim CU, Lew W, Williams MA, Wu H, Zhang L, Chen X, Escarpe PA, Mendel DB, Laver WG, Stevens RC. 1998. Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. J Med Chem 41:2451-2460. http://dx.doi.org/10.1021/jm980162u.
6. CDC. 2009. Update: influenza activity: United States, September 28, 2008-January 31, 2009. MMWR Morb Mortal Wkly Rep 58:115-119.
7. Wolfe C, Greenwald I, Chen L. 2010. Pandemic (H1N1) 2009 and oseltamivir resistance in hematology/oncology patients. Emerg Infect Dis 16:1809-1811. http://dx.doi.org/10.3201/eid1611.101053.
8. Moore C, Galiano M, Lackenby A, Abdelrahman T, Barnes R, Evans MR, Fegan C, Froude S, Hastings M, Knapper S, Litt E, Price N, Salmon R, Temple M, Davies E. 2011. Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A (H1N1) 2009 virus in a hematology unit. J Infect Dis 203:18-24. http://dx.doi.org/10.1093/infdis /jiq007.
9. Chen LF, Dailey NJ, Rao AK, Fleischauer AT, Greenwald I, Deyde VM, Moore ZS, Anderson DJ, Duffy J, Gubareva LV, Sexton DJ, Fry AM, Srinivasan A, Wolfe CR. 2011. Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients-North Carolina, 2009. J Infect Dis 203: 838-846. http://dx.doi.org/10.1093/infdis/jiq124.
10. CDC. 2009. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis-North Carolina, 2009. MMWR Morb Mortal Wkly Rep 58:969-972.
11. Le QM, Wertheim HF, Tran ND, van Doorn HR, Nguyen TH, Horby P. 2010. A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N Engl J Med 362:86-87. http://dx.doi.org/10.1056 /NEJMc0910448.
12. Hurt AC, Hardie K, Wilson NJ, Deng YM, Osbourn M, Leang SK, Lee RT, Iannello P, Gehrig N, Shaw R, Wark P, Caldwell N, Givney RC, Xue L, Maurer-Stroh S, Dwyer DE, Wang B, Smith DW, Levy A, Booy R, Dixit R, Merritt T, Kelso A, Dalton C, Durrheim D, Barr IG. 2012. Characteristics of a widespread community cluster of H275Y oseltamivirresistant A(H1N1)pdm09 influenza in Australia. J Infect Dis 206:148- 157. http://dx.doi.org/10.1093/infdis/jis337.
13. Hurt AC, Holien JK, Barr IG. 2009. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob Agents Chemother 53:4433-4440. http://dx.doi.org/10.1128/AAC.00334-09.
14. Hurt AC, Lee RT, Leang SK, Cui L, Deng YM, Phuah SP, Caldwell N, Freeman K, Komadina N, Smith D, Speers D, Kelso A, Lin RT, Maurer- Stroh S, Barr IG. 2011. Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. Euro Surveill 16:pii-19884.
15. Hurt AC, Holien JK, Parker M, Kelso A, Barr IG. 2009. Zanamivirresistant influenza viruses with a novel neuraminidase mutation. J Virol 83:10366-10373. http://dx.doi.org/10.1128/JVI.01200-09.
16. Nguyen HT, Fry AM, Loveless PA, Klimov AI, Gubareva LV. 2010. Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin Infect Dis 51:983-984. http: //dx.doi.org/10.1086/656439.
17. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, Nguyen KH, Pham ND, Ngyen HH, Yamada S, Muramoto Y, Horimoto T, Takada A, Goto H, Suzuki T, Suzuki Y, Kawaoka Y. 2005. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437:1108. http://dx.doi .org/10.1038/4371108a.
18. Baz M, Abed Y, McDonald J, Boivin G. 2006. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis 43:1555-1561. http://dx.doi .org/10.1086/508777.
19. Mishin VP, Hayden FG, Gubareva LV. 2005. Susceptibilities of antiviralresistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 49:4515-4520. http://dx.doi.org/10.1128/AAC.49.11 .4515-4520.2005.
20. Wang D, Sleeman K, Huang W, Nguyen HT, Levine M, Cheng Y, Li X, Tan M, Xing X, Xu X, Klimov AI, Gubareva LV, Shu Y. 2013. Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir. Antivir Res 97:240-244. http://dx.doi.org /10.1016/j.antiviral.2012.12.013.
21. Dapat C, Suzuki Y, Saito R, Kyaw Y, Myint YY, Lin N, Oo HN, Oo KY, Win N, Naito M, Hasegawa G, Dapat IC, Zaraket H, Baranovich T, Nishikawa M, Saito T, Suzuki H. 2010. Rare influenza A (H3N2) variants with reduced sensitivity to antiviral drugs. Emerg Infect Dis 16:493-496. http://dx.doi.org/10.3201/eid1603.091321.
22. Fujisaki S, Takashita E, Yokoyama M, Taniwaki T, Xu H, Kishida N, Sato H, Tashiro M, Imai M, Odagiri T. 2012. A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs. Biochem Biophys Res Commun 429:51-56. http://dx.doi.org/10.1016/j .bbrc.2012.10.095.
23. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, Butler EN, Wallis TR, Klimov AI, Gubareva LV. 2008. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 52:3284-3292. http://dx.doi.org/10.1128/AAC.00555-08.
24. Carr S, Ilyushina NA, Franks J, Adderson EE, Caniza M, Govorkova EA, Webster RG. 2011. Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer. Pediatr Infect Dis J 30:284 -288. http://dx.doi.org/10.1097/INF .0b013e3181ff863b.
25. Samson M, Pizzorno A, Abed Y, Boivin G. 2013. Influenza virus resistance to neuraminidase inhibitors. Antivir Res 98:174-185. http://dx.doi .org/10.1016/j.antiviral.2013.03.014.
26. Ferraris O, Lina B. 2008. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J Clin Virol 41:13-19. http://dx.doi .org/10.1016/j.jcv.2007.10.020.
27. Belser JA, Bridges CB, Katz JM, Tumpey TM. 2009. Past, present, and possible future human infection with influenza virusAsubtype H7. Emerg Infect Dis 15:859-865. http://dx.doi.org/10.3201/eid1506.090072.
28. Malik Peiris JS. 2009. Avian influenza viruses in humans. Rev Sci Tech 28:161-173.
29. Ip DK, Liao Q, Wu P, Gao Z, Cao B, Feng L, Xu X, Jiang H, Li M, Bao J, Zheng J, Zhang Q, Chang Z, Li Y, Yu J, Liu F, Ni MY, Wu JT, Cowling BJ, Yang W, Leung GM, Yu H. 2013. Detection of mild to moderate influenza A/H7N9 infection by China's national sentinel surveillance system for influenza-like illness: case series. BMJ 346:f3693. http://dx.doi.org /10.1136/bmj.f3693.
30. Chen H, Yuan H, Gao R, Zhang J, Wang D, Xiong Y, Fan G, Yang F, Li X, Zhou J, Zou S, Yang L, Chen T, Dong L, Bo H, Zhao X, Zhang Y, Lan Y, Bai T, Dong J, Li Q, Wang S, Zhang Y, Li H, Gong T, Shi Y, Ni X, Li J, Zhou J, Fan J, Wu J, Zhou X, Hu M, Wan J, Yang W, Li D, Wu G, Feng Z, Gao GF, Wang Y, Jin Q, Liu M, Shu Y. 2014. Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study. Lancet 383:714-721. http://dx.doi.org /10.1016/S0140-6736(14)60111-2.
31. Yuan J, Zhang L, Kan X, Jiang L, Yang J, Guo Z, Ren Q. 2013. Origin and molecular characteristics of a novel 2013 avian influenza A(H6N1) virus causing human infection in Taiwan. Clin Infect Dis 57:1367-1368. http://dx.doi.org/10.1093/cid/cit479.
32. World Health Organization. 1980. A revision of the system of nomenclature for influenza viruses: a WHO memorandum. Bull World Health Organ 58:585-591.
33. Russell RJ, Haire LF, Stevens DJ, Collins PJ, Lin YP, Blackburn GM, Hay AJ, Gamblin SJ, Skehel JJ. 2006. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443:45-49. http://dx.doi.org/10.1038/nature05114.
34. Yu H, Cowling BJ, Feng L, Lau EH, Liao Q, Tsang TK, Peng Z, Wu P, Liu F, Fang VJ, Zhang H, Li M, Zeng L, Xu Z, Li Z, Luo H, Li Q, Feng Z, Cao B, Yang W, Wu JT, Wang Y, Leung GM. 2013. Human infection with avian influenza A H7N9 virus: an assessment of clinical severity. Lancet 382:138-145. http://dx.doi.org/10.1016/S0140-6736(13)61207-6.
35. Abdelwhab EM, Veits J, Mettenleiter TC. 2014. Prevalence and control of H7 avian influenza viruses in birds and humans. Epidemiol Infect 142: 896-920. http://dx.doi.org/10.1017/S0950268813003324.
36. Ke Y, Wang Y, Liu S, Guo J, Zhang W, Yuan X, Zhang N, Wang Z, Song H, Huang L, Chen Z. 2013. High severity and fatality of human infections with avian influenza A(H7N9) infection in China. Clin Infect Dis 57: 1506-1507. http://dx.doi.org/10.1093/cid/cit371.
37. World Health Organization. 2014. WHO risk assessment: human infections with avian influenza A(H7N9) virus 28 February 2014. World Health Organization, Geneva, Switzerland.
38. Li Q, Zhou L, Zhou M, Chen Z, Li F, Wu H, Xiang N, Chen E, Tang F, Wang D, Meng L, Hong Z, Tu W, Cao Y, Li L, Ding F, Liu B, Wang M, Xie R, Gao R, Li X, Bai T, Zou S, He J, Hu J, Xu Y, Chai C, Wang S, Gao Y, Jin L, Zhang Y, Luo H, Yu H, He J, Li Q, Wang X, Gao L, Pang X, Liu G, Yan Y, Yuan H, Shu Y, Yang W, Wang Y, Wu F, Uyeki TM, Feng Z. 2014. Epidemiology of human infections with avian influenza A(H7N9) virus in China.NEngl J Med 370:520-532. http://dx.doi.org/10 .1056/NEJMoa1304617.
39. Belser JA, Gustin KM, Pearce MB, Maines TR, Zeng H, Pappas C, Sun X, Carney PJ, Villanueva JM, Stevens J, Katz JM, Tumpey TM. 2013. Pathogenesis and transmission of avian influenza A (H7N9) virus in ferrets and mice. Nature 501:556 -559. http://dx.doi.org/10.1038 /nature12391.
40. Hu Y, Lu S, Song Z, Wang W, Hao P, Li J, Zhang X, Yen HL, Shi B, Li T, Guan W, Xu L, Liu Y, Wang S, Zhang X, Tian D, Zhu Z, He J, Huang K, Chen H, Zheng L, Li X, Ping J, Kang B, Xi X, Zha L, Li Y, Zhang Z, Peiris M, Yuan Z. 2013. Association between adverse clinical outcome in human disease caused by novel influenzaAH7N9virus and sustained viral shedding and emergence of antiviral resistance. Lancet 381:2273-2279. http://dx.doi.org/10.1016/S0140-6736(13)61125-3.
41. Hai R, Schmolke M, Leyva-Grado VH, Thangavel RR, Margine I, Jaffe EL, Krammer F, Solorzano A, Garcia-Sastre A, Palese P, Bouvier NM. 2013. Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. Nat Commun 4:2854. http://dx.doi.org/10.1038/ncomms3854.
42. Orozovic G, Orozovic K, Jarhult JD, Olsen B. 2014. Study of oseltamivir and zanamivir resistance-related mutations in influenza viruses isolated from wild mallards in Sweden. PLoS One 9:e89306. http://dx.doi.org/10 .1371/journal.pone.0089306.
43. Stoner TD, Krauss S, Turner JC, Seiler P, Negovetich NJ, Stallknecht DE, Frase S, Govorkova EA, Webster RG. 2012. Susceptibility of avian influenza viruses of the N6 subtype to the neuraminidase inhibitor oseltamivir. Antivir Res 93:322-329. http://dx.doi.org/10.1016/j.antiviral .2011.12.013.
44. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. 2000. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A 97:6108-6113. http://dx.doi.org/10 .1073/pnas.100133697.
45. Potier M, Mameli L, Belisle M, Dallaire L, Melancon SB. 1979. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferylalpha- D-N-acetylneuraminate) substrate. Anal Biochem 94:287-296. http://dx.doi.org/10.1016/0003-2697(79)90362-2.
46. Okomo-Adhiambo M, Nguyen HT, Abd EA, Sleeman K, Fry AM, Gubareva LV. 2014. Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria. Influenza Other Respir Viruses 8:258- 265. http://dx.doi.org/10.1111/irv.12215.
47. Puzelli S, Di TL, Fabiani C, Campitelli L, De Marco MA, Capua I, Aguilera JF, Zambon M, Donatelli I. 2005. Serological analysis of serum samples from humans exposed to avian H7 influenza viruses in Italy between 1999 and 2003. J Infect Dis 192:1318-1322. http://dx.doi.org/10 .1086/444390.
48. Tweed SA, Skowronski DM, David ST, Larder A, Petric M, Lees W, Li Y, Katz J, Krajden M, Tellier R, Halpert C, Hirst M, Astell C, Lawrence D, Mak A. 2004. Human illness from avian influenza H7N3, British Columbia. Emerg Infect Dis 10:2196-2199. http://dx.doi.org/10.3201/eid1012.040961.
49. Nguyen-Van-Tam JS, Nair P, Acheson P, Baker A, Barker M, Bracebridge S, Croft J, Ellis J, Gelletlie R, Gent N, Ibbotson S, Joseph C, Mahgoub H, Monk P, Reghitt TW, Sundkvist T, Sellwood C, Simpson J, Smith J, Watson JM, Zambon M, Lightfoot N. 2006. Outbreak of low pathogenicity H7N3 avian influenza in the UK, including associated case of human conjunctivitis. Euro Surveill 11:E060504.
50. Belser JA, Davis CT, Balish A, Edwards LE, Zeng H, Maines TR, Gustin KM, Martinez IL, Fasce R, Cox NJ, Katz JM, Tumpey TM. 2013. Pathogenesis, transmissibility, and ocular tropism of a highly pathogenic avian influenza A (H7N3) virus associated with human conjunctivitis. J Virol 87:5746-5754. http://dx.doi.org/10.1128/JVI.00154-13.
51. Belser JA, Blixt O, Chen LM, Pappas C, Maines TR, Van HN, Donis R, Busch J, McBride R, Paulson JC, Katz JM, Tumpey TM. 2008. Contemporary North American influenza H7 viruses possess human receptor specificity: implications for virus transmissibility. Proc Natl Acad SciUSA 105:7558-7563. http://dx.doi.org/10.1073/pnas.0801259105.
52. Kurtz J, Manvell RJ, Banks J. 1996. Avian influenza virus isolated from a woman with conjunctivitis. Lancet 348:901-902. http://dx.doi.org/10 .1016/S0140-6736(05)64783-6.
53. Koopmans M, Wilbrink B, Conyn M, Natrop G, van der Nat H, Vennema H, Meijer A, van SJ, Fouchier R, Osterhaus A, Bosman A. 2004. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 363:587-593. http://dx.doi.org/10.1016/S0140-6736(04)15589-X.
54. Fouchier RA, Schneeberger PM, Rozendaal FW, Broekman JM, Kemink SA, Munster V, Kuiken T, Rimmelzwaan GF, Schutten M, Van Doornum GJ, Koch G, Bosman A, Koopmans M, Osterhaus AD. 2004. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci U S A 101:1356-1361. http://dx.doi.org/10.1073/pnas.0308352100.
55. Qi Y, Fan H, Qi X, Zhu Z, Guo X, Chen Y, Ge Y, Zhao K, Wu T, Li Y, Shan Y, Zhou M, Shi Z, Wang H, Cui L. 2014. A novel pyrosequencing assay for the detection of neuraminidase inhibitor resistance-conferring mutations among clinical isolates of avian H7N9 influenza virus. Virus Res 179:119-124. http://dx.doi.org/10.1016/j.virusres.2013.10.026.
56. Wu Y, Bi Y, Vavricka CJ, Sun X, Zhang Y, Gao F, Zhao M, Xiao H, Qin C, He J, Liu W, Yan J, Qi J, Gao GF. 2013. Characterization of two distinct neuraminidases from avian-origin human-infecting H7N9 influenza viruses. Cell Res 23:1347-1355. http://dx.doi.org/10 .1038/cr.2013.144.
57. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. 1998. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 178:1257-1262. http://dx.doi .org/10.1086/314440.
58. Nguyen HT, Fry AM, Gubareva LV. 2012. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir Ther 17:159-173. http://dx.doi.org/10.3851/IMP2067.
59. Boltz DA, Douangngeun B, Phommachanh P, Sinthasak S, Mondry R, Obert C, Seiler P, Keating R, Suzuki Y, Hiramatsu H, Govorkova EA, Webster RG. 2010. Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People's Democratic Republic. J Gen Virol 91:949-959. http://dx.doi .org/10.1099/vir.0.017459-0.
60. Abed Y, Baz M, Boivin G. 2009. A novel neuraminidase deletion mutation conferring resistance to oseltamivir in clinical influenza A/H3N2 virus. J Infect Dis 199:180-183. http://dx.doi.org/10.1086/595736.
61. Abed Y, Baz M, Boivin G. 2006. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir Ther 11:971-976.
62. Pizzorno A, Bouhy X, Abed Y, Boivin G. 2011. Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. J Infect Dis 203:25-31. http://dx.doi.org/10 .1093/infdis/jiq010.
63. Zurcher T, Yates PJ, Daly J, Sahasrabudhe A, Walters M, Dash L, Tisdale M, McKimm-Breschkin JL. 2006. Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro. J Antimicrob Chemother 58:723-732. http://dx.doi.org/10.1093/jac/dkl321.
64. Okomo-Adhiambo M, Demmler-Harrison GJ, Deyde VM, Sheu TG, Xu X, Klimov AI, Gubareva LV. 2010. Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrob Agents Chemother 54:1834-1841. http://dx.doi.org/10.1128/AAC .01608-09.
65. Varghese JN, Smith PW, Sollis SL, Blick TJ, Sahasrabudhe A, McKimm- Breschkin JL, Colman PM. 1998. Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure 6:735-746. http://dx.doi.org/10.1016/S0969 -2126(98)00075-6.
66. Yen HL, Herlocher LM, Hoffmann E, Matrosovich MN, Monto AS, Webster RG, Govorkova EA. 2005. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother 49:4075-4084. http://dx.doi.org/10.1128 /AAC.49.10.4075-4084.2005.
67. Yen HL, Hoffmann E, Taylor G, Scholtissek C, Monto AS, Webster RG, Govorkova EA. 2006. Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J Virol 80: 8787-8795. http://dx.doi.org/10.1128/JVI.00477-06.
68. Hurt AC, Lowther S, Middleton D, Barr IG. 2010. Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model. Antivir Res 87:361-366. http://dx.doi.org/10 .1016/j.antiviral.2010.06.009.
69. Ho HT, Hurt AC, Mosse J, Barr I. 2007. Neuraminidase inhibitor drug susceptibility differs between influenza N1 and N2 neuraminidase following mutagenesis of two conserved residues. Antivir Res 76:263-266. http: //dx.doi.org/10.1016/j.antiviral.2007.08.002.
70. Wang MZ, Tai CY, Mendel DB. 2002. Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir. Antimicrob Agents Chemother 46:3809- 3816. http://dx.doi.org/10.1128/AAC.46.12.3809-3816.2002.
71. Nguyen HT, Sheu TG, Mishin VP, Klimov AI, Gubareva LV. 2010. Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob Agents Chemother 54:3671-3677. http://dx.doi.org /10.1128/AAC.00581-10.
72. van d, V, Veldhuis Kroeze EJ, Stittelaar KJ, Linster M, Van der Linden A, Schrauwen EJ, Leijten LM, van, AG, Schutten M, Kuiken T, Osterhaus AD, Fouchier RA, Boucher CA, Herfst S. 2011. Multidrug resistant 2009 A/H1N1 influenza clinical isolate with a neuraminidase I223R mutation retains its virulence and transmissibility in ferrets. PLoS Pathog 7:e1002276. http://dx.doi.org/10.1371/journal.ppat.1002276.
73. Eshaghi A, Patel SN, Sarabia A, Higgins RR, Savchenko A, Stojios PJ, Li Y, Bastien N, Alexander DC, Low DE, Gubbay JB. 2011. Multidrugresistant pandemic (H1N1) 2009 infection in immunocompetent child. Emerg Infect Dis 17:1472-1474. http://dx.doi.org/10.3201/eid1708 .102004.